Diana Hamdan

Ms. Diana Hamdan

Kansas City University of Medicine and Biosciences, Kansas City, Kansas, USA
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in American Journal of Physiology-Renal Physiology
Verified
Journal Article
Closed access
PDF file
DHDiana Hamdan
Diana Hamdan
LRLisa A. Robinson
Lisa A. Robinson
Excessive infiltration of immune cells into the kidney is a key feature of acute and chronic kidney diseases. The family of chemokines comprises key drivers of this process. Fractalkine [chemokine (C-X3-C motif) ligand 1 (CX3CL1)] is one of two unique chemokines synthesized as a transmembrane protein that undergoes proteolytic cleavage to generate a soluble species. Through interacting with its cognate receptor, chemokine (C-X3-C motif) receptor 1 (CX3CR1), CX3CL1 was originally shown to act as a conventional chemoattractant in the soluble form and as an adhesion molecule in the transmembrane form. Since then, other functions of CX3CL1 beyond leukocyte recruitment have been described, including cell survival, immunosurveillance, and cell-mediated cytotoxicity. This review summarizes diverse roles of CX3CL1 in kidney disease and potential uses as a therapeutic target and novel biomarker. As the CX3CL1-CX3CR1 axis has been shown to contribute to both detrimental and protective effects in various kidney diseases, a thorough understanding of how the expression and function of CX3CL1 are regulated is needed to unlock its therapeutic potential.

27 October 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
JZJenny W. Zhang
Jenny W. Zhang
Precious Ochuwa ImokhaiPrecious Ochuwa Imokhai
Precious Ochuwa Imokhai
DLDanny Lee
Danny Lee
DHDiana Hamdan
Diana Hamdan
TMTrisha Mahajan
Trisha Mahajan
Amanda BrooksAmanda Brooks
Amanda Brooks
The medical condition of pregnancy-associated breast cancer (PABC) requires oncologists to determine the best way to protect both the mother and the fetus during cancer treatment. The safety profile of taxanes, including paclitaxel and docetaxel, in the second and third trimesters of pregnancy remains unclear despite well-established anthracycline-based regimens (e.g., doxorubicin). High-risk breast cancer subtypes such as triple negative breast cancer (TNBC) and human epidermal growth factor receptor (HER2)-positive disease require taxane chemotherapy as standard treatment in nonpregnant patients. Objective: This paper aims to gather available data about the safety, timing and fetal outcomes related to taxane chemotherapy during PABC, focusing on pharmacological and clinical guidance. Methods: A targeted literature review of PubMed and Scopus databases was performed to identify case series, cohort studies, and clinical guidelines addressing taxane use during pregnancy. This was not conducted as a formal systematic review or meta-analysis, but as a comprehensive narrative synthesis of available data. Results: The pharmacological properties of paclitaxel and docetaxel limit their placental transfer. Paclitaxel has not been associated with increased congenital anomalies; however, the long-term developmental data remain limited. Similarly, docetaxel administration shows no increase in major malformations. The most common approach used in PABC is to administer anthracyclines first and taxanes after 16–18 weeks’ gestation. The adverse effects experienced by pregnant patients match those experienced by nonpregnant patients. Conclusions: Taxanes can be used with caution after the first trimester in patients with PABC, especially in high-risk cases following anthracycline treatment. The absence of randomized trials combined with limited developmental data highlight the need for more standardized treatment approaches, aligning with current guideline recommendations.

18 September 2025 in International Urogynecology Journal
Verified
Journal Article
Closed access
PDF file
DHDiana Hamdan
Diana Hamdan
JAJ. Tyrone Adcock
J. Tyrone Adcock

1 February 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
DHDiana Hamdan
Diana Hamdan
Precious Ochuwa ImokhaiPrecious Ochuwa Imokhai
Precious Ochuwa Imokhai
AKAlexandra Konvalina
Alexandra Konvalina
BNBaoKhanh Nguyen
BaoKhanh Nguyen
MAMaha Alhoda
Maha Alhoda
Amanda BrooksAmanda Brooks
Amanda Brooks
Background: Neuroimaging protocols for neurotologic disease are often developed without consideration of patient-specific factors such as biological differences, clinical presentation variability, and comorbidities. This lack of tailored design contributes to insufficient detection, delayed diagnosis, and inappropriate treatment. Objectives: To critically examine the literature on diagnostic limitations of neuroimaging for neurotologic lesions and identify gaps in protocol validation, accuracy, and clinical translation. Methods: A systematic review of PubMed and Google Scholar was conducted, focusing on studies published between 2015 and 2025 that evaluated diagnostic imaging outcomes in patients with neurotologic lesions. Eligible studies included prospective cohorts, retrospective analyses, and consensus statements. Outcomes of interest included the sensitivity and specificity of imaging modalities, prevalence of misdiagnosis, and the influence of biological, anatomical, and clinical variability on diagnostic performance. Results: The literature demonstrates that neurotologic disorders are frequently associated with diagnostic challenges, including atypical clinical presentations, overlapping symptoms, and stroke mimics, which complicate image interpretation. Standard magnetic resonance imaging (MRI) protocols often miss subtle or early ischemic changes, resulting in delayed intervention. Few studies stratify outcomes by patient characteristics, and most protocols were developed in generalized populations without comprehensive validation. Evidence on advanced imaging modalities (positron emission tomography (PET), single-photon emission computed tomography (SPECT), high-resolution MRI) remains limited, and large-scale prospective studies addressing diagnostic accuracy gaps are lacking. In summary, a total of 27 studies met inclusion criteria. Conclusions: Current neuroimaging methods are insufficiently validated across diverse patient populations, contributing to the underdiagnosis and mismanagement of neurotologic disease. Improved diagnostic accuracy will require large-scale, prospective research, standardized outcome reporting, and imaging protocols designed to account for patient-specific variability.

26 May 2025 in Cureus
Verified
Journal Article
Open access
PDF file
DHDiana Hamdan
Diana Hamdan
ANAbbigail Niewchas
Abbigail Niewchas
ANAmbrose Loc T. Ngo
Ambrose Loc T. Ngo
MWMichael Weaver
Michael Weaver
In scientific reporting, ‘spin’ refers to presenting neutral or negative outcomes in a manner that infers favorable results. Spin can be especially problematic in the abstracts of randomized control trials, leading to an incorrect interpretation of trial outcomes, and potentially impacting subsequent studies, patient care, and policy decisions. The present study aims to evaluate the presence of spin in the abstracts of registered randomized control trials published in allergy and immunology journals. A systematic search of the PubMed database was performed to identify randomized controlled trials of human subjects registered in a clinical trial registry with a test and control group and a nonsignificant primary endpoint. A total of 1,248 articles were screened and 66 abstracts met full inclusion criteria. Thirty-five of the 66 (53%) abstracts were found to contain one or more elements of spin, among which 11 (31.4%) had spin in the title, 29 (82.9%) in the abstract results, and 30 (85.7%) in the abstract conclusion. Industry-sponsored trials did not contain more spin compared to other funding sources (p=0.62). High rates of spin may adversely affect the interpretation and integration of new research. Careful evaluation is recommended when reviewing abstracts lacking statistically significant primary outcomes.

4 June 2026 in Cureus
Verified
Journal Article
Open access
CBCassandra Blau
Cassandra Blau
DHDiana Hamdan
Diana Hamdan
PRPeter Reisdorf
Peter Reisdorf
BSBrandon Shin
Brandon Shin
JAJack T Adcock
Jack T Adcock
JPJohn Paulson
John Paulson
Background: Pneumonia is a serious respiratory infection that affects patients across all age groups. While it typically responds to treatment, patients with pre-existing comorbidities are at increased risk of poor outcomes. Hypertension (HTN) is a common condition that may coexist in patients with pneumonia. Although pneumonia and HTN have been studied separately, there is limited evidence regarding their combined effect on clinical outcomes, including hospital length of stay (LOS), treatment duration, and recovery trajectory.